Boron Compounds Inhibit Arginase Enzyme Activity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for pathological states associated with arginase enzyme activity, such as pulmonary hypertension, erectile dysfunction, and atherosclerosis, are inadequate due to the enzyme's role in regulating nitric oxide and polyamine levels, leading to imbalanced signaling and disease progression.
Innovation Solution
Development of boron-containing compounds according to Formulae I and II, which act as inhibitors of arginase activity, providing therapeutic agents to treat various diseases by inhibiting arginase enzymes and restoring balanced nitric oxide and polyamine levels.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If arginase activity is not inhibited, then nitric oxide levels remain unregulated, but pathological states such as pulmonary hypertension, erectile dysfunction, and atherosclerosis progress due to imbalanced signaling
Solution Approach 1:
The patent extracts and isolates the arginase enzyme activity as the specific target for inhibition. By developing compounds that selectively bind to and inhibit arginase, the invention removes the harmful enzymatic activity responsible for imbalanced nitric oxide and polyamine levels, thereby treating pathological states without affecting other physiological processes
Solution Approach 2:
The invention changes the biochemical parameter of arginase activity by introducing compounds that reduce enzyme function. The boron-containing compounds and other inhibitors described modify the enzymatic reaction rate, shifting the balance of substrate conversion from pathological to physiological levels, thereby restoring proper signaling
2Ease of operation
If current treatments are used for arginase-related pathological states, then some symptom management may occur, but the underlying mechanism of imbalanced nitric oxide and polyamine levels remains unaddressed
Solution Approach 1:
The patent introduces arginase inhibitor compounds as intermediary substances that mediate between the pathological state and the desired therapeutic outcome. These compounds act as chemical mediators that specifically interfere with the arginase pathway, restoring balance to nitric oxide and polyamine levels without requiring complex surgical or lifestyle interventions
Solution Approach 2:
The invention enables the body's own signaling systems to restore balance by removing the pathological block. By inhibiting arginase, the treatment allows endogenous nitric oxide synthase and polyamine synthesis pathways to function properly, letting the body's natural mechanisms correct the imbalances without continuous external intervention
Data Source
AI summary
Compounds according to Formula I and Formula II are potent inhibitors of Arginase I and II activity:where R1, R2, R3, R4, R5, R6, R7, R8, R9, D, M, X, and Y are defined as set forth in the specification. The invention also provides pharmaceutical compositions of the compounds and methods of their use for treating or preventing a disease or a condition associated with arginase activity.